Agendia

We were founded in 2003 as a spin-off from the Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital in Amsterdam, for the purpose of pursuing commercialization of molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development. In 2004, we launched the initial version of our MammaPrint? breast cancer recurrence test in Europe. In 2006, we subjected MammaPrint to an international independent retrospective validation which led to the selection of MammaPrint as the exclusive molecular diagnostic stratification tool for the MINDACT trial, featuring 6,600 patients at 109 institutions in nine European countries. In 2007, MammaPrint became the first IVDMIA to obtain 510(k) clearance from the FDA, and after receipt of the regulatory clearance, we made MammaPrint commercially available in the United States in 2008. Since 2007, MammaPrint has received an additional four FDA clearances